ErikSupratikMittraMDPhD
Nuclear Medicine • Portland, ORAssociate Professor of Diagnostic Radiology; Chief, Nuclear Medicine & Molecular Imaging; Oregon Health & Science University
Dr. Mittra is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3181 SW Sam Jackson Park Rd
Portland, OR 97239Phone+1 503-418-0990Fax+1 503-494-4982
Education & Training
Stanford Health CareFellowship, PET/CT Clinical Oncology, 2008 - 2009
Stanford Health Care-Sponsored Stanford UniversityResidency, Nuclear Medicine, 2006 - 2008
Stony Brook Medicine/University HospitalInternship, Internal Medicine, 2005 - 2006
Stony Brook University Health Sciences Center School of MedicineClass of 2005
Certifications & Licensure
OR State Medical License 2017 - 2025
CA State Medical License 2007 - 2018- American Board of Nuclear Medicine Nuclear Medicine
Clinical Trials
- 4D-CT-based Ventilation Imaging for Adaptive Functional Guidance in Radiotherapy Start of enrollment: 2009 Dec 01
- A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours Start of enrollment: 2012 Sep 06
- 18F-FDOPA PET/CT or PET/MRI in Measuring Tumors in Patients With Newly-Diagnosed or Recurrent Gliomas Start of enrollment: 2014 Dec 01
- Join now to see all
Publications & Presentations
PubMed
- 45 citationsEvaluation of trabecular mechanical and microstructural properties in human calcaneal bone of advanced age using mechanical testing, μCT, and DXAErik Mittra, Clinton T. Rubin, Barry L. Gruber, Yi-Xian Qin
Journal of Biomechanics. 2008-01-01 - 144 citations177Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival an...Jonathan R. Strosberg, Martyn Caplin, Pamela L. Kunz, Philippe Ruszniewski, Lisa Bodei
The Lancet. Oncology. 2021-11-15 - 1785 citationsPhase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine TumorsJonathan R. Strosberg, Ghassan El-Haddad, Edward M. Wolin, Andrew Eugene Hendifar, James C. Yao
The New England Journal of Medicine. 2017-01-11
Authored Content
- It May Be Time to Stop Classifying Theranostics as a Radiology SubspecialtyJuly 2019
- It May Be Time to Stop Classifying Theranostics as a Radiology SubspecialtyJuly 2019
- Navigating the Evolving Landscape of Neuroendocrine TumorsJanuary 2019
Press Mentions
Clinical Challenges: Nuclear Medicine and Neuroendocrine TumorsApril 30th, 2020- Clinical Challenges: Nuclear Medicine and Biochemically Recurrent Prostate CancerApril 23rd, 2020
PET/MRI Evaluation of Cardiac AmyloidApril 13th, 2017- Join now to see all
Committees
- Member, OHSU MD/PhD Committee 2018 - Present
- Chair, SNMMI Committee on Chapters 2018 - Present
- Board Member, SNMMI Outreach Committee 2016 - Present
- Board Member, SNMMI Therapy Center of Excellence 2016 - Present
- Chair, SNMMI Targeted Radiotherapy Working Group 2016 - Present
- Board Member, SNMMI PET Center of Excellence 2014 - Present
- Chair, ISCD CME Committee 2017 - 2019
Professional Memberships
- Society of Nuclear Medicine & Molecular ImagingMember
- International Society of Clinical DensitometryMember
Other Languages
- Bengali
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
